Quote | Repare Therapeutics Inc. (NASDAQ:RPTX)
Last: | $3.89 |
---|---|
Change Percent: | -1.79% |
Open: | $3.97 |
Close: | $3.89 |
High: | $4.18 |
Low: | $3.76 |
Volume: | 68,469 |
Last Trade Date Time: | 07/22/2024 03:00:00 am |
News | Repare Therapeutics Inc. (NASDAQ:RPTX)
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Canada NewsWire AEC invests US$7.5M into Amplitude Ventures US$192M Fund II to support the growth of life science startups, establishing a full-time Amplitude presence in ...
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine mon...
Message Board Posts | Repare Therapeutics Inc. (NASDAQ:RPTX)
Subject | By | Source | When |
---|---|---|---|
I believe we going to break 15 on | Gator44 | investorshub | 06/08/2022 3:12:26 PM |
I believe we going hit 15 this week | ElusTrade | investorshub | 06/05/2022 4:00:24 PM |
Not alone bought on the news sold Friday | akamaii | investorshub | 06/04/2022 3:55:49 PM |
$RPTX: We just busted-through to a "LUCKY THIRTEEN | Just-Keep-Trying | investorshub | 06/03/2022 7:55:23 PM |
$RPTX: Something is UP!!!! INDEED, a shinny-new GREEN | Just-Keep-Trying | investorshub | 06/03/2022 7:46:57 PM |
News, Short Squeeze, Breakout and More Instantly...
Repare Therapeutics Inc. Company Name:
RPTX Stock Symbol:
NASDAQ Market:
Repare Therapeutics Inc. Website:
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund Canada NewsWire AEC invests US$7.5M into Amplitude Ventures US$192M Fund II to support the growth of life science startups, establishing a full-time Amplitude presence in ...
Overall response of 18.2% in heavily pretreated patients across gastrointestinal tumors with target alterations regardless of prior irinotecan exposure Prolonged clinical benefit in patients with CRC, with 40% of irinotecan-naïve patients receiving treatment for greater than nine mon...
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced the first patient has been dosed in the Company’s camonsertib monotherapy non-small cell lung cancer (NSCLC) expansion of th...